How much of the 2025 EPS growth is organic versus a result of 2024 one-time items?

Pfizer's 2024 reported guidance included roughly $0.30 of non-recurring benefit, mainly from $1.2 billion of one-time Paxlovid revenue and a favorable tax rate from Pillar 2 timing and audit settlements. Measured against the 2024 baseline of $2.45 to $2.65, which excludes these items, the 2025 guidance of $2.80 to $3.00 implies operational growth of 10% to 18%. Investors should focus on that baseline comparison rather than the headline 2024 figure of $2.75 to $2.95.

What is the main revenue headwind Pfizer expects in 2025?

The company cites a net unfavorable revenue impact of approximately $1 billion from changes to Medicare Part D under the Inflation Reduction Act, including the sunset of the Coverage Gap Discount Program and new manufacturer discounts in the initial and catastrophic coverage phases. This is partly offset by the $2,000 out-of-pocket cap and the Prescription Payment Plan. Generic and biosimilar competition adds an additional expected headwind of about $0.6 billion.

Will Pfizer repurchase shares in 2025, and how does that affect EPS guidance?

No. Pfizer's Adjusted diluted EPS guidance assumes approximately 5.74 billion diluted weighted-average shares and no share repurchases in 2024 or 2025. Any buybacks made later would be upside to the EPS guidance, all else equal.

What drives the expected margin improvement and what is the outlook for cost savings?

Pfizer has delivered $4.0 billion of net operating expense savings through 2024 under its cost realignment program and expects an additional $500 million in 2025. The 2025 SI&A and R&D expense range of $24.0 to $26.0 billion reflects these savings. Gross margin improvement is expected to come from the first phase of the Manufacturing Optimization Program, with initial net cost savings expected in the latter part of 2025.

Does the 2025 guidance include potential acquisitions?

No. The guidance does not assume the completion of any business development transactions that were not completed as of December 16, 2024. Future acquisitions, including any deals that could change the revenue or share count outlook, would require updated guidance. The guidance also uses exchange rates from mid-November 2024 and does not reflect subsequent currency movements.

PFE 8-K: Regulation FD — Dec 17, 2024

01—Abstract

Summary

Summary of the 8-K filed December 17, 2024. Cited figures are marked; the original filing is the authoritative source.

Pfizer issued its full-year 2025 guidance on December 17, 2024 and reaffirmed its October 29, 2024 guidance for 2024.

For 2025 it expects revenue of $61.0 to $64.0 billion^a and Adjusted diluted EPS of $2.80 to $3.00. Against a 2024 baseline that excludes about $1.2 billion of non-recurring Paxlovid revenue and about $0.30 of non-recurring EPS benefit, management projects roughly flat to 5% operational revenue growth and 10% to 18% operational Adjusted EPS growth. The 2025 revenue outlook already reflects a roughly $1 billion net headwind from Medicare Part D redesign under the Inflation Reduction Act and about $0.6 billion of generic and biosimilar competition.

The guidance rests on continued cost discipline. Pfizer says it has achieved its goal of $4.0 billion^b in net operating expense savings through 2024 under its cost realignment program and expects an additional $500 million in 2025. It projects 2025 Adjusted SI&A plus R&D expenses of $24.0 to $26.0 billion, and it expects initial net savings from the first phase of its Manufacturing Optimization Program in late 2025, aimed at gross margin improvement.

Guidance assumes about 5.74 billion diluted shares and no share repurchases in 2024 or 2025, and it excludes any business development deals not completed by December 16, 2024. Investors should note the optical nature of much of the 2025 EPS growth. The 2024 base is flattered by one-time items, and 2025 loses Haleon equity income from Adjusted earnings after Pfizer reduced its Haleon stake in Q4 2024.

Adjusted EPS guidance also assumes a higher effective tax rate of about 15%^c, compared with about 13% in 2024. The release is furnished under Regulation FD rather than filed, and the detailed presentation is available on Pfizer's investor website.

02—Key points

Key Highlights

2025 revenue guidance of $61.0 to $64.0 billion, with operational growth of roughly flat to 5% versus the 2024 baseline midpoint of $61.3 billion excluding non-recurring items
2025 Adjusted diluted EPS guidance of $2.80 to $3.00, implying 10% to 18% operational growth from the 2024 baseline midpoint of $2.55
2024 reaffirmed: revenue of $61.0 to $64.0 billion and Adjusted diluted EPS of $2.75 to $2.95, including roughly $1.2 billion of non-recurring Paxlovid revenue and about $0.30 of EPS benefit
Cost realignment program achieved its goal of $4.0 billion in net operating expense savings through 2024, with an additional $500 million targeted for 2025
Combined 2025 Adjusted SI&A and R&D expenses guided to $24.0 to $26.0 billion
Headwinds include about $1 billion net revenue impact from IRA Part D redesign and about $0.6 billion from generic and biosimilar competition
Haleon equity method income will no longer be included in Adjusted earnings in 2025, and the 2025 tax rate is assumed at about 15% versus about 13% in 2024

03—Questions

Frequently Asked Questions

How much of the 2025 EPS growth is organic versus a result of 2024 one-time items?
Pfizer's 2024 reported guidance included roughly $0.30 of non-recurring benefit, mainly from $1.2 billion of one-time Paxlovid revenue and a favorable tax rate from Pillar 2 timing and audit settlements. Measured against the 2024 baseline of $2.45 to $2.65, which excludes these items, the 2025 guidance of $2.80 to $3.00 implies operational growth of 10% to 18%. Investors should focus on that baseline comparison rather than the headline 2024 figure of $2.75 to $2.95.
What is the main revenue headwind Pfizer expects in 2025?
The company cites a net unfavorable revenue impact of approximately $1 billion from changes to Medicare Part D under the Inflation Reduction Act, including the sunset of the Coverage Gap Discount Program and new manufacturer discounts in the initial and catastrophic coverage phases. This is partly offset by the $2,000 out-of-pocket cap and the Prescription Payment Plan. Generic and biosimilar competition adds an additional expected headwind of about $0.6 billion.
Will Pfizer repurchase shares in 2025, and how does that affect EPS guidance?
No. Pfizer's Adjusted diluted EPS guidance assumes approximately 5.74 billion diluted weighted-average shares and no share repurchases in 2024 or 2025. Any buybacks made later would be upside to the EPS guidance, all else equal.
What drives the expected margin improvement and what is the outlook for cost savings?
Pfizer has delivered $4.0 billion of net operating expense savings through 2024 under its cost realignment program and expects an additional $500 million in 2025. The 2025 SI&A and R&D expense range of $24.0 to $26.0 billion reflects these savings. Gross margin improvement is expected to come from the first phase of the Manufacturing Optimization Program, with initial net cost savings expected in the latter part of 2025.
Does the 2025 guidance include potential acquisitions?
No. The guidance does not assume the completion of any business development transactions that were not completed as of December 16, 2024. Future acquisitions, including any deals that could change the revenue or share count outlook, would require updated guidance. The guidance also uses exchange rates from mid-November 2024 and does not reflect subsequent currency movements.

04—Continue

← View all 8-K filings